Drospirenone reduces inflammatory cytokines, vascular endothelial growth factor (VEGF) and nerve growth factor (NGF) expression in human endometriotic stromal cells

Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism.

W. Oelkers, Jean Michel Foidart, N. Dombrovicz et al. · The Journal of Clinical Endocrinology & Metabolism · 1995 · 223 citations

The novel progestin drospirenone and its natural counterpart progesterone: Biochemical profile and antiandrogenic potential

Ulrike Fuhrmann, Rolf Krattenmacher, Emily P. Slater et al. · Contraception · 1996 · 195 citations

Hormonal Contraceptive, Novel Progestin Drospirenone, Natural Counterpart Progesterone +9

Drospirenone: a Novel Progestogen with Antimineralocorticoid and Antiandrogenic Activity

Peter Muhn, Ulrike Fuhrmann, Karl Heinrich Fritzemeier et al. · Annals of the New York Academy of Sciences · 1995 · 183 citations

Hormonal Contraceptive, Endocrine Mechanism, Medicine +11

Long-term oral contraceptive pills and postoperative pain management after laparoscopic excision of ovarian endometrioma: a randomized controlled trial

Renato Seracchioli, Mohamed Mabrouk, Clarissa Frascà et al. · Fertility and Sterility · 2009 · 160 citations

Gynecologic Surgery, Laparoscopy, Contraception +10

Progesterone and progestational compounds attenuate tumor necrosis factor alpha–induced interleukin-8 production via nuclear factor kappaB inactivation in endometriotic stromal cells

Sayako Horie, Tasuku Harada, Masahiro Mitsunari et al. · Fertility and Sterility · 2005 · 159 citations · Full text

Inflammation, Cytokine, Uterine Receptivity +8